{"name":"BioAtla","slug":"bioatla","ticker":"BCAB","exchange":"NASDAQ","domain":"bioatla.com","description":"BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquarter","hq":"San Diego, CA","founded":0,"employees":"41","ceo":"Jay M. Short","sector":"Oncology / Antibody-Drug Conjugates","stockPrice":4.41,"stockChange":0.01,"stockChangePercent":0.23,"marketCap":"$7M","metrics":{"revenue":2000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":63095000,"netIncome":-69776000,"cash":7118000,"dividendYield":0,"peRatio":-3.3,"fiscalYear":"FY2021"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"BA3011 patent cliff ($0.0B at risk)","drug":"BA3011","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"BA3021 patent cliff ($0.0B at risk)","drug":"BA3021","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BA3071","genericName":"BA3071","slug":"ba3071","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"CAB-AXL-ADC","genericName":"CAB-AXL-ADC","slug":"cab-axl-adc","indication":"AXL-positive solid tumors (Phase 2 development)","status":"phase_2"}]}],"pipeline":[{"name":"BA3071","genericName":"BA3071","slug":"ba3071","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"CAB-AXL-ADC","genericName":"CAB-AXL-ADC","slug":"cab-axl-adc","phase":"phase_2","mechanism":"CAB-AXL-ADC is an antibody-drug conjugate that targets AXL-expressing cancer cells and delivers cytotoxic payload upon binding.","indications":["AXL-positive solid tumors (Phase 2 development)"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"BioAtla Announces FDA Clearance of Investigational New Drug (IND) Application for BA3011","summary":"BioAtla announced that the FDA has cleared the IND application for BA3011, a BCMA-targeting ADC for the treatment of multiple myeloma.","drugName":"BA3011","sentiment":"positive"},{"date":"2023-11-14","type":"deal","headline":"BioAtla Enters into Collaboration Agreement with Merck KGaA","summary":"BioAtla announced a collaboration agreement with Merck KGaA to develop and commercialize its ADCs for the treatment of cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNM0p0NzkwcUxacVBNUm1BQktfa2hIaEtGSWd0bFkzV3lSNUhyREdhdC1UVmR3SEMyUWxLTmpJWDgwYW1pODBCOTV1bWlZX3BBY2Vubzh3WU1sZXl5UXpJRWJEa0dBX3V4U0tESDNkWFpqcmVpcDc1TkdscDZLWGpWWjN6dVVnLXUxRmM2U1cwSFdhMFNWX1lLcGk0SFlXcUppREpVLXhnaVBHNkVoWW1qUTB4cExQQ2hv?oc=5","date":"2026-04-01","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga","headline":"12 Health Care Stocks Moving In Wednesday's Pre-Market Session","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNZlAxb3RJREVlaVJ0NXVsZUdfOTJrYTlxbm1jSnZQNGVEd0pwTGplYl9aZ0EwQ2lFS0plREl4TlhVVUFsU0ZMQ2E1b0xnOU1zc3lrVzZuSUpMV00wckpnZURvbUlNTjI5RWtYZUprRlotaHlpcWxKTHFBSXVZSmNhU0lIZEVZbG9MQUtSWlZxX0h5cC1JQ3VHSWttcDFNV2tuQURiWU1lTWY5c3A5R0RQQ2pvbVBHbUdi?oc=5","date":"2026-03-31","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga","headline":"12 Health Care Stocks Moving In Tuesday's After-Market Session","sentiment":"neutral"},{"date":"2026-03-31","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOT1NnUjUxUVVGT2EzZExac3EzQmUyZ2luUEpjVGhNanBBZUxkZjRMSWNfTXE2QVdDQ3gyMmY1TnVEQmpmVzRjdUFPUUlzUHR2RlVyRHFOcUxiQUwwRk8zVzlObnJNUnhpUWFLMFdBMTNtUmFzcWVHMEw3RTJ0aW1iSWtZOTBMZEdBckxlR05NOFRoODhBbUR0M2Q0UHg1TjRPVG1GWmNFeTB4Xzk2end0a1FaZ3NBQS1BWU1odlhn?oc=5","date":"2026-03-02","type":"pipeline","source":"Stock Titan","summary":"Biotech BioAtla to shed 70% of staff while weighing asset sales - Stock Titan","headline":"Biotech BioAtla to shed 70% of staff while weighing asset sales","sentiment":"neutral"},{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxQb0NMQWk1RVFjbXN2ZmpReVlreXAzSDFkZ3ZaOGpPWkR6dWZkNXdlLVY2NDVmMGpKeDVnT1JBTFN5ZmRrNDRtbTY1VGRHdjFZM3NMZTI0TFZKZy1kazdIMTdxbEhad252TFRxUlFaQWh5VExrbWVkS2l1Qk9DeDVQNnNhTzk3RTAwRUwtVjlpcGFpaFI3VjZiQnlGY0toU3RXQmlfNmpia25GNVVwbTBKcnFEbDVqc1BBSUpUSGpWRG9VbU9reDdXbElFYjNvQVNDdmZNcWhiMmxUc1Rz?oc=5","date":"2025-11-21","type":"pipeline","source":"GlobeNewswire","summary":"BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing - GlobeNewswire","headline":"BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOZkhMbXlSek5FSWVmdFdkRkM0RTdiczRNbmFYYWVYQVlUUnhHT0NaYmRlMlhCUnBDS0RLdDlIcUFXRklnVWdIOEE0aWhibTJJRThyaXpmd1VkZnV4OWlzdXVoNGVwV1RKVjNiRWxFNEZRenVtekJYa04waGF4MEFQMm44MFV1dHpyTG56aVlUaDJxV0VTSjZJbm5Tem0wTnNJVWl1SEs4U2U1dGlIT01hX1Y2XzBfNlZ6MmtrT2JkTQ?oc=5","date":"2025-08-13","type":"pipeline","source":"Investing.com","summary":"BioAtla’s SWOT analysis: oncology biotech’s stock faces cash crunch - Investing.com","headline":"BioAtla’s SWOT analysis: oncology biotech’s stock faces cash crunch","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-21","type":"pipeline","source":"simplywall.st","summary":"Here's Why We're A Bit Worried About BioAtla's (NASDAQ:BCAB) Cash Burn Situation - simplywall.st","headline":"Here's Why We're A Bit Worried About BioAtla's (NASDAQ:BCAB) Cash Burn Situation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPR0tVLUt6Mm15Sng0MS1rOVpid21zY2JVZExLYjg1UE05RmJ0ampDUWhyMjRfMktHYVBJcEtTdGZJVjJNTVVOMlhRMlJ5OVF3Z09NTnVMZEJhQmFNTFBnYUI1TnVGQ1NkemdvTGg4a2tQSzFkVHNFVVl0dEdST0g3UkJKMVZaNGd3Wmk3VlIxZDhwMWZzM0V4NjRXaGZaVjQ?oc=5","date":"2025-03-28","type":"deal","source":"Fierce Biotech","summary":"BioAtla lays off 30% of staff, hunts out partners for ADC and cancer antibody - Fierce Biotech","headline":"BioAtla lays off 30% of staff, hunts out partners for ADC and cancer antibody","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNX000SkpwVUU0bEt2ZElNVWNsRC1aVU9sVHVIMTBKdmZkNGVjVko1REZLWWV6OExNQU1VSXBjdzBxWW5menlxVW00RVhrZmlia1BrcXRlTHNvZjdXUmZKWlVlU2xzaDBfNTVGY3NUYWxUcU1FRURaQ1FFY243U1NEck9LZTNqY05rb0JKYlRWV3BmREtwWG5WaEVody1VQ0wzUzJWTjUwTzVHc2l2bEF3ODBR?oc=5","date":"2024-10-08","type":"regulatory","source":"Seeking Alpha","summary":"BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy - Seeking Alpha","headline":"BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy","sentiment":"neutral"}],"patents":[{"drugName":"BA3011","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0},{"drugName":"BA3021","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":2,"phaseCounts":{"phase_1":1,"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["AstraZeneca","Merck & Co.","Bristol Myers Squibb"],"therapeuticFocus":["Oncology","Antibody-Drug Conjugates"],"financials":{"source":"sec_edgar+yahoo","revenue":300000,"revenuePeriod":"2021-12-31","revenueHistory":[{"value":300000,"period":"2021-12-31"},{"value":300000,"period":"2021-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":63095000,"rdSpendHistory":[{"period":"2025-12-31","value":43573000},{"period":"2024-12-31","value":63095000},{"period":"2023-12-31","value":103731000},{"period":"2022-12-31","value":79347000}],"sgaSpend":17732000,"operatingIncome":-59305000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-59305000},{"period":"2024-12-31","value":-73943000},{"period":"2023-12-31","value":-129687000},{"period":"2022-12-31","value":-108140000}],"netIncome":-69776000,"netIncomeHistory":[{"period":"2025-12-31","value":-59607000},{"period":"2024-12-31","value":-69776000},{"period":"2023-12-31","value":-123462000},{"period":"2022-12-31","value":-106482000}],"eps":-1.01,"epsHistory":[{"period":"2025-12-31","value":-1.01},{"period":"2024-12-31","value":-60.049071},{"period":"2023-12-31","value":-129},{"period":"2022-12-31","value":-49.788608}],"cash":7118000,"cashHistory":[{"period":"2025-12-31","value":7118000},{"period":"2024-12-31","value":49046000},{"period":"2023-12-31","value":111471000},{"period":"2022-12-31","value":215507000}],"totalAssets":52422000,"totalLiabilities":50017000,"totalDebt":6200000,"equity":-36189000,"operatingCashflow":-48204000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-48204000},{"period":"2024-12-31","value":-71936000},{"period":"2023-12-31","value":-104015000},{"period":"2022-12-31","value":-90420000}],"capex":-98000,"capexHistory":[{"period":"2023-12-31","value":-98000},{"period":"2022-12-31","value":-268000},{"period":"2021-12-31","value":-924000}],"freeCashflow":-48204000,"dividendsPaid":null,"buybacks":null,"employees":41,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":3260000,"ebit":-9255000,"ebitda":-9236000,"period":"2025-12-31","revenue":2000000,"epsBasic":-8,"netIncome":-9784000,"rdExpense":7995000,"epsDiluted":-8,"grossProfit":null,"operatingIncome":-9255000},{"sga":4250000,"ebit":-13789000,"ebitda":-13733000,"period":"2025-09-30","revenue":0,"epsBasic":-13.5,"netIncome":-15778000,"rdExpense":9539000,"epsDiluted":-13.5,"grossProfit":null,"operatingIncome":-13789000},{"sga":4963000,"ebit":-18647000,"ebitda":-18532000,"period":"2025-06-30","revenue":0,"epsBasic":-16,"netIncome":-18711000,"rdExpense":13684000,"epsDiluted":-16,"grossProfit":null,"operatingIncome":-18647000},{"sga":5259000,"ebit":-17614000,"ebitda":-17431000,"period":"2025-03-31","revenue":0,"epsBasic":-13,"netIncome":-15334000,"rdExpense":12355000,"epsDiluted":-13,"grossProfit":null,"operatingIncome":-17614000},{"sga":4594000,"ebit":-16244000,"ebitda":-16016000,"period":"2024-12-31","revenue":0,"epsBasic":-12.809137,"netIncome":-14884000,"rdExpense":11650000,"epsDiluted":-12.809137,"grossProfit":null,"operatingIncome":-16244000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":4.41,"previousClose":4.4,"fiftyTwoWeekHigh":71.5,"fiftyTwoWeekLow":3.92,"fiftyTwoWeekRange":"3.92 - 71.5","fiftyDayAverage":6.21,"twoHundredDayAverage":22.43,"beta":0.79,"enterpriseValue":6372474,"forwardPE":-3.3,"priceToBook":-0.15,"priceToSales":3.66,"enterpriseToRevenue":3.19,"enterpriseToEbitda":-0.11,"pegRatio":0,"ebitda":-58332000,"ebitdaMargin":0,"freeCashflow":-22801624,"operatingCashflow":-48204000,"totalDebt":6200000,"debtToEquity":0,"currentRatio":0.37,"returnOnAssets":-110.8,"returnOnEquity":0,"analystRating":"","recommendationKey":"none","numberOfAnalysts":0,"targetMeanPrice":0,"targetHighPrice":0,"targetLowPrice":0,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":5.6,"institutionHeldPercent":20.4,"sharesOutstanding":1659612,"floatShares":1383053,"sharesShort":147268,"shortRatio":2.87,"shortPercentOfFloat":8.9,"epsTrailing":-50.5,"epsForward":-1.34,"revenuePerShare":1.7,"bookValue":-28.51,"officers":[{"age":67,"name":"Dr. Jay M. Short Ph.D.","title":"Co-Founder, CEO & Chairman"},{"age":61,"name":"Dr. Eric L. Sievers M.D.","title":"Chief Medical Officer"},{"age":null,"name":"Ms. Susie  Melody","title":"Senior Vice President of Human Resources"},{"age":null,"name":"Dr. Cathy  Chang Ph.D.","title":"Senior Vice President of Research & Development"},{"age":null,"name":"Dr. Gerhard  Frey Ph.D.","title":"Senior Vice President of Technology Development"},{"age":null,"name":"Ms. Monica  Sullivan","title":"Senior Vice President of Intellectual Property & Contracts"},{"age":null,"name":"Ms. Sheri  Lydick","title":"Chief Commercial Officer"},{"age":null,"name":"Lisa M. Pelton","title":"Accounting Manager"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.bioatla.com","phone":"858 558 0708"}}